Star Surgical Company reports fourth quarter and fiscal year 2025 results, highlighting financial performance, strategic initiatives, and future outlook.

Star Surgical Company has shared its fourth quarter and fiscal year 2025 financial results, revealing both challenges and opportunities for growth. Interim Co-CEOs Warren Faust and Deborah Andrews highlighted the company's transition year and expressed optimism for a rebound in 2026, particularly in the Chinese market. The earnings call provided key insights into financial performance, strategic initiatives, and future outlook, which are crucial for investors and stakeholders.

Financial Performance

In the fourth quarter of 2025, Star Surgical reported total net sales of $57.8 million, up from $49 million in the same quarter of the previous year. This increase was primarily driven by a resurgence in the Chinese market, although sales were impacted by inventory adjustments. Specifically, net sales in China reached $17.5 million, a significant increase from $7.8 million in the prior year quarter.

Year-over-Year Comparisons

• Total Net Sales: $57.8 million (Q4 2025) vs. $49 million (Q4 2024)
• Net Sales in China: $17.5 million (Q4 2025) vs. $7.8 million (Q4 2024)
• Gross Profit Margin: Increased to 75.7% from 64.7% due to operational efficiencies and cost reductions.
• Adjusted EBITDA: A loss of $200,000, a significant improvement from a loss of $20.8 million in the previous year.

Despite these positive metrics, total operating expenses rose to $66.6 million, influenced by costs associated with a terminated merger transaction. Excluding merger-related costs, operating expenses decreased by 8.2% from the previous year, showcasing the company's commitment to cost management.

Strategic Initiatives

Star Surgical's leadership highlighted several strategic initiatives aimed at revitalizing growth and enhancing operational efficiency. The company is particularly focused on its EVO ICL product line, which continues to gain market share in refractive surgery, especially as a shift away from laser procedures occurs. Key initiatives include:

• Expansion of EVO ICL Indications: The U.S. market has expanded its age range indication for EVO, now approved for myopia treatment in adults aged 21 to 60, adding approximately 8 million potential candidates.
• Manufacturing Enhancements: The company is advancing its Swiss manufacturing facility, which aims to produce EVO and EVO plus products, thus avoiding U.S.-China tariffs and providing scalability.
• Innovation Pipeline: A renewed focus on innovation has led to the launch of EVO plus in China, the first new lens in over a decade, anticipated to drive growth and profitability.
• Customer Engagement: Star Surgical emphasizes collaborative efforts with customers to ensure effective sales strategies and improved training on EVO products.

“We firmly believe that Star has everything it takes to deliver on our growth, profitability, and innovation goals,” stated Warren Faust during the call.

Future Outlook

Looking ahead, Star Surgical management provided insights into their expectations for 2026. While no specific financial guidance was issued, there is a strong focus on returning to profitability and capitalizing on growth opportunities. Key outlook highlights include:

• Sales Growth: The company anticipates a significant increase in sales driven by stabilized inventory levels and improved market conditions in China.
• Cost Management: Continued cost discipline is expected to sustain lower operating expenses, targeting a run rate aligned with the $225 million annualized operating expense communicated earlier.
• Profitability Goals: Management is determined to achieve profitability in 2026, although gross margins may experience slight declines due to higher inventory costs from the Swiss manufacturing facility.
• Cash Generation: While cash flows may dip modestly in the near term, the expectation is to resume cash generation in the latter half of 2026, ending the year with a healthier cash balance than 2025.

Concluding Assessment

In conclusion, Star Surgical Company is navigating a transitional phase, with a clear strategy aimed at growth, profitability, and innovation. The leadership's focus on operational improvements, cost management, and product expansion—especially in the Chinese market—positions the company well for recovery in 2026. With a solid foundation in refractive surgery and a commitment to innovation, Star is poised to capitalize on the growing demand for lens-based corrective procedures. Investors should keep a close eye on the company's execution of its strategic initiatives and upcoming product launches, as these will be critical in determining future performance.

Overall, the outlook appears promising, with management expressing confidence in their ability to drive shareholder value moving forward.